UNSPSC 51332508: Droperidol

This classification denotes a butyrophenone with the molecular formula C22H22FN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O9U0F09D5X, chemically known as 2h-benzimidazol-2-one, 1-(1-(4-(4-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridinyl)-1,3-dihydro- but generally known as droperidol, which bears US NIH Compound Identifier 3168. European Medicines Agency schedules Droperidol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06410MIG.

UNSPSC 51332508 Droperidol is a Commodity code that encompasses pharmaceutical products, but recent state and local solicitations under this code do not limit themselves to droperidol alone — they reflect a much broader procurement pattern in which state and local health agencies and purchasing cooperatives source general pharmaceuticals, over-the-counter products, and specialized health-related systems. State and local governments are buying generic multi-source pharmaceuticals, naloxone, drug deactivation systems, and direct-to-manufacturer prescription fulfillment capabilities through this code. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving multiple states including Oregon). The issuing bodies are predominantly health-focused public agencies and multi-state procurement cooperatives rather than traditional municipal or county general-services buyers.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026, soliciting 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, gathering vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program; and the Minnesota Department of Administration's MMCAP RFP S1070000015802, posted January 20, 2026, seeking manufacturers of generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with proposals due March 26, 2026, and contract effectiveness targeted for July 1, 2026. The MMCAP procurement reflects a cooperative purchasing model spanning multiple states and requiring compliance with cGMP, DSCSA, and FDA standards, with evaluation weighted heavily toward price competitiveness (75 percent) and administrative compliance (25 percent). No explicit set-aside designations appear in the recent opportunities.